209 reports of this reaction
1.2% of all TIMOLOL MALEATE reports
#20 most reported adverse reaction
GLAUCOMA is the #20 most commonly reported adverse reaction for TIMOLOL MALEATE, manufactured by Bausch & Lomb Incorporated. There are 209 FDA adverse event reports linking TIMOLOL MALEATE to GLAUCOMA. This represents approximately 1.2% of all 16,822 adverse event reports for this drug.
Patients taking TIMOLOL MALEATE who experience glaucoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GLAUCOMA is a less commonly reported adverse event for TIMOLOL MALEATE, but still significant enough to appear in the safety profile.
In addition to glaucoma, the following adverse reactions have been reported for TIMOLOL MALEATE:
The following drugs have also been linked to glaucoma in FDA adverse event reports:
GLAUCOMA has been reported as an adverse event in 209 FDA reports for TIMOLOL MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GLAUCOMA accounts for approximately 1.2% of all adverse event reports for TIMOLOL MALEATE, making it a notable side effect.
If you experience glaucoma while taking TIMOLOL MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.